GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » EV-to-FCF

ADC Therapeutics (ADC Therapeutics) EV-to-FCF : -1.90 (As of May. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ADC Therapeutics's Enterprise Value is $285.53 Mil. ADC Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-150.12 Mil. Therefore, ADC Therapeutics's EV-to-FCF for today is -1.90.

The historical rank and industry rank for ADC Therapeutics's EV-to-FCF or its related term are showing as below:

ADCT' s EV-to-FCF Range Over the Past 10 Years
Min: -100.18   Med: -2.4   Max: 1.59
Current: -1.9

During the past 8 years, the highest EV-to-FCF of ADC Therapeutics was 1.59. The lowest was -100.18. And the median was -2.40.

ADCT's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.34 vs ADCT: -1.90

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), ADC Therapeutics's stock price is $3.755. ADC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.770. Therefore, ADC Therapeutics's PE Ratio for today is At Loss.


ADC Therapeutics EV-to-FCF Historical Data

The historical data trend for ADC Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics EV-to-FCF Chart

ADC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -12.00 -5.11 -0.72 0.14

ADC Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.49 0.80 0.14 -1.74

Competitive Comparison of ADC Therapeutics's EV-to-FCF

For the Biotechnology subindustry, ADC Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADC Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADC Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where ADC Therapeutics's EV-to-FCF falls into.



ADC Therapeutics EV-to-FCF Calculation

ADC Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=285.531/-150.12
=-1.90

ADC Therapeutics's current Enterprise Value is $285.53 Mil.
ADC Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-150.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ADC Therapeutics  (NYSE:ADCT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

ADC Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.755/-2.770
=At Loss

ADC Therapeutics's share price for today is $3.755.
ADC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.770.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


ADC Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ADC Therapeutics (ADC Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.